- Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.
- The partnership will leverage Ginkgo’s cell programming platform and Selecta’s ImmTOR platform to create potentially transformative enzymatic therapies.
- Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
- Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
- Related: Selecta In-Licenses Rights To IgG Protease Platform.
- Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
Why Plug Plower And Enphase Energy Shares Are Popping Off
Plug Power Inc (NASDAQ: PLUG) and Enphase Energy Inc (NASDAQ: ENPH) shares are trading higher by 5.30% to $27.22 and 6.92% to $313.07 respectively.
